Selank
TKPRPGP tuftsin analogue — ≠ Semax ≠ Adamax; no US FDA anxiety assumption.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. Selank is the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), a tuftsin analogue with a C-terminal Pro-Gly-Pro extension. PubChem CID 11765600 (hard-separate from Semax CID 9811102 and Adamax TBD); formula C33H57N11O9 / MW 751.9; CAS 129954-34-3. Selank ≠ Semax; ≠ Adamax (batch D); ≠ tuftsin alone. Russian clinical program papers exist for anxiety indications in that jurisdiction’s literature; do not assume a US FDA-approved anxiety drug object. This drawer marks papers. It is not use advice.
Bottom line
Human literature includes Russian-language anxiety-treatment optimization reports. Mechanistic and rodent work covers GABAergic gene expression, stress/anxiety models, ethanol-memory interactions, and a joint Selank–Semax connectomic imaging study. Tuftsin-analogue reviews provide class context. Refuse interchangeable “nootropic peptide” glow with Semax.
Papers
Human / clinical-program (jurisdiction-sensitive)
PMID 26356395 — Medvedev 2015
Tested: optimization of treatment of anxiety disorders with Selank (clinical-program report).
Does not show: a US FDA approval package, or equivalence to Semax stroke literature.
PMID 34396551 — Doyno 2021
Tested: secondary review of sedative-hypnotic / GABA-impacting agents that mentions Selank among other agents.
Does not show: a primary Selank pivotal RCT.
Mechanism / behavioral (preclinical & cellular)
PMID 28293190 — Filatova 2017
Tested: GABA, Selank, and olanzapine effects on GABAergic neurotransmission gene expression in IMR-32 cells.
Does not show: human clinical efficacy by itself.
PMID 26924987 — Volkova 2016
Tested: Selank administration effects on expression of genes involved in GABAergic neurotransmission.
Does not show: a labeled anxiety indication outside study jurisdiction framing.
PMID 28280289 — Kasian 2017
Tested: Selank enhances diazepam’s anxiolytic effect under unpredictable chronic mild stress in rats.
Does not show: human combination-therapy approval.
PMID 31625062 — Kolik 2019
Tested: Selank protection against ethanol-induced memory impairment via BDNF regulation in rat brain regions.
Does not show: human AUD cognition indication.
PMID 36322304 — Konstantinopolsky 2022
Tested: Selank attenuates aversive signs of morphine withdrawal in rats.
Does not show: human addiction-therapy approval.
PMID 14552529 — Kozlovskaya / Kozlovskii 2003
Tested: optimizing action of synthetic peptide Selank on conditioned active avoidance reflex in rats.
Does not show: modern human RCT endpoints.
PMID 30255741 — Vyunova 2018
Tested: molecular aspects of heptapeptide Selank biological activity (peptide anxiolytic framing).
Does not show: a new primary clinical trial.
Class / joint imaging context
PMID 28745220 — Siebert 2017
Tested: review of tuftsin properties and analogs (Selank as tuftsin analogue class context).
Does not show: Selank-specific pivotal efficacy.
PMID 32342318 — Panikratova 2020
Tested: functional connectomic approach to studying Selank and Semax effects (imaging; both objects).
Does not show: that Selank and Semax are interchangeable.
What is not established
US FDA approval as an anxiety or nootropic drug. Interchangeability with Semax or Adamax. That rodent GABA/BDNF papers equal labeled human efficacy worldwide. Product identity of unlabeled vials vs characterized Selank. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
26356395 34396551 28293190 26924987 28280289 31625062 36322304 14552529 30255741 28745220 32342318
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.